Figures & data
Figure 1. Schematic showing the study design and immunotherapy model. Mice were sensitized with ovalbumin (OVA) (10 μg) on day 7, then given 1-MT and kynurenine (KYN) intraperitoneal (i.p.) before a boost with OVA on the indicated day (1 μg). Mice were sacrificed on the day after the last challenge with 10% OVA.
Table 1. Comparison of serum OVA-specific IgE and inflammatory cytokines in BALF between groups in high dose OVA AIT.
Table 2. Comparisons between groups in cell numbers of total, eosinophils, lymphocytes, and neutrophils in BALF.
Table 3. Comparisons between groups in Treg cells and RORγt+ T cells of spleen and lung.
Table 4. Comparison between groups in mRNA-Foxp3/β-actin and mRNA-RORγt/β-actin of lung.
Figure 2. Representative histological images of the indoleamine 2,3 dioxygenase (IDO) inhibitor, 1-methyl tryptophan (1-MT), and the tryptophan metabolite, kynurenine (KYN), on the allergen-specific immunotherapy (AIT). Representative lung sections stained with hematoxylin and eosin (H&E) from the indicated group: (a) control, (b) treated with ovalbumin (OVA) plus AIT, (c) asthma, (d) stimulated with OVA + AIT then 1-MT, (e) stimulated with OVA + AIT, then 1-MT + KYN. Data represent mean ± SEM of 2 independent experiments with n ≥ 3 mice per experiment.
Figure 3. Effect of tryptophan metabolite on airway hyper-reactivity.
